本文選題：絕經(jīng)后骨質(zhì)疏松癥 + 唑來膦酸��； 參考：《浙江大學(xué)》2017年碩士論文

【摘要】：目的:研究分析使用唑來膦酸治療66例絕經(jīng)后女性骨質(zhì)疏松癥患者的臨床療效。方法:選擇2012-2016年間在我院骨科住院行靜脈滴注唑來膦酸治療的絕經(jīng)后女性骨質(zhì)疏松癥患者共66例,年齡范圍51-97歲,平均(68.606±8.621)歲�；颊呤褂眠騺盱⑺�(密固達(dá))5mg(100ml)靜脈滴注1次,滴注時(shí)間15min以上,并且患者每天基礎(chǔ)服用骨礦化促進(jìn)藥物骨化三醇0.5μg/d及碳酸鈣片1片/天。在使用唑來膦酸治療前、治療1年后分別檢測患者腰椎總骨密度、右側(cè)髖關(guān)節(jié)骨密度,以及血清總Ⅰ型膠原氨基酸延長肽(t-P11NP)、N端骨鈣素(N-MID)、β-膠原特殊序列(β-CTX)、25-羥基維生素D(25-OH-VD)這些骨代謝指標(biāo),并對(duì)檢測結(jié)果進(jìn)行統(tǒng)計(jì)分析。比較患者骨密度、血清骨代謝指標(biāo)在治療前后的變化差異,以及在各年齡段(51-60歲,61-70歲,70歲以上)治療前后的差異�！酢踅Y(jié)果:患者腰椎總骨密度、血清總Ⅰ型膠原氨基酸延長肽、N端骨鈣素、β-膠原特殊序列、25-羥基維生素D在治療1年后與治療前相比有顯著差異(P0.05)。全髖關(guān)節(jié)骨密度在治療1年后與治療前比較,雖有所增加,但差異卻無統(tǒng)計(jì)學(xué)意義(P0.05)。51-60歲,61-70歲,70歲以上三個(gè)年齡分組中腰椎總骨密度、血清總Ⅰ型膠原氨基酸延長肽、N端骨鈣素、β-膠原特殊序列、25-羥基維生素D在治療1年后與治療前相比均有顯著差異(P0.05)。而右氈關(guān)節(jié)骨密度與治療前比較雖均有增加,但差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:靜脈滴注唑來膦酸治療絕經(jīng)后女性骨質(zhì)疏松癥,不僅能有效提高患者腰椎的總骨密度,同時(shí)也可改善患者的血清中骨代謝指標(biāo),并且對(duì)各年齡段的絕經(jīng)后骨質(zhì)疏松癥女性均有明確的臨床效果。
[Abstract]:Objective: To study and analyze the clinical efficacy of zoledronic acid in the treatment of 66 postmenopausal women with osteoporosis. Methods: 66 cases of postmenopausal women with postmenopausal osteoporosis treated in 2012-2016 years in our department of orthopedics were treated with zazolonic acid. The average age range was 51-97 years old (68.606 + 8.621) years. The patients were treated with zoledrine. Acid (dense) 5mg (100ml) intravenous infusion 1 times, infusion time more than 15min, and patients on a daily basis of bone mineralization to promote ossification of three alcohol 0.5 mu g/d and Calcium Carbonate Tablets 1 tablets / days. Before the treatment of zoledronic acid, the total bone mineral density, right hip joint bone density, and serum total type I collagen amino group were detected 1 years before the treatment of zoledronic acid. Acid lengthening peptide (t-P11NP), N terminal Osteocalcin (N-MID), beta collagen special sequence (beta -CTX) and 25- hydroxyl vitamin D (25-OH-VD) were used to analyze the bone metabolic indices, and to compare the results of bone mineral density and serum bone metabolism before and after treatment (51-60 years old, 61-70 years old, over 70 years old). Results: the total BMD of the lumbar spine, the total serum type I collagen amino acid lengthening peptide, the N end osteocalcin, the special sequence of beta collagen, and the 25- hydroxyvitamin D were significantly different from those before the treatment (P0.05). The total hip joint bone density was increased after 1 years of treatment, although the difference was not statistically significant. The total BMD of lumbar vertebrae in P0.05.51-60 years, 61-70 years old and over 70 years old in three age groups, serum total type I collagen amino acid lengthening peptide, N end osteocalcin, and beta collagen special sequence, 25- hydroxyl vitamin D were significantly different from before treatment (P0.05) compared with before treatment (P0.05), but the right felt joint bone density increased although compared with before treatment, but poor There is no statistical significance (P0.05). Conclusion: intravenous drip of zoledronic acid in the treatment of postmenopausal women osteoporosis can not only improve the total bone mineral density of the lumbar spine, but also improve the index of bone metabolism in the patients' serum, and have a clear clinical effect on postmenopausal women with osteoporosis.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R580
，

本文編號(hào)：2040600